Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Zhang, Wei; Tan, Yifei; Li, Yuquan; Liu, Jiang

Zhang, Wei; Tan, Yifei; Li, Yuquan; Liu, Jiang.

Afiliación

Zhang W; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Tan Y; Department of Ultrasonography, West China Second University Hospital, Sichuan University, Chengdu, China.
Li Y; Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Liu J; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Front Immunol ; 14: 1234142, 2023.

Article en En | MEDLINE | ID: mdl-37622124

Asunto(s)

Inhibidores de Puntos de Control Inmunológico; Neoplasias; Humanos; Bases de Datos Factuales; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Linfocitos; Neoplasias/tratamiento farmacológico; Neutrófilos; Oportunidad Relativa

Palabras clave

biomarker; cancer treatment; immune checkpoint inhibitors; immune-related adverse events; neutrophil to lymphocyte ratio

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google